Literature DB >> 25002534

TRP14 inhibits osteoclast differentiation via its catalytic activity.

Sohyun Hong1, Jeong-Eun Huh1, Soo Young Lee1, Jae-Kyung Shim2, Sue Goo Rhee3, Woojin Jeong4.   

Abstract

We previously reported the inhibitory role of thioredoxin-related protein of 14 kDa (TRP14), a novel disulfide reductase, in nuclear factor-κB (NF-κB) activation, but its biological function has remained to be explored. Here, we evaluated the role of TRP14 in the differentiation and function of osteoclasts (OCs), for which NF-κB and cellular redox regulation have been known to be crucial, using RAW 264.7 macrophage cells expressing wild-type TRP14 or a catalytically inactive mutant, as well as its small interfering RNA. TRP14 depletion enhanced OC differentiation, actin ring formation, and bone resorption, as well as the accumulation of reactive oxygen species (ROS). TRP14 depletion promoted the activation of NF-κB, c-Jun NH2-terminal kinase, and p38, the expression of c-Fos, and the consequent induction of nuclear factor of activated T cell, cytoplasmic 1 (NFATc1), a key determinant of osteoclastogenesis. However, pretreatment with N-acetylcysteine or diphenylene iodonium significantly reduced the OC differentiation, as well as the ROS accumulation and NF-κB activation, that were enhanced by TRP14 depletion. Furthermore, receptor activator of NF-κB ligand (RANKL)-induced ROS accumulation, NF-κB activation, and OC differentiation were inhibited by the ectopic expression of wild-type TRP14 but not by its catalytically inactive mutant. These results suggest that TRP14 regulates OC differentiation and bone resorption through its catalytic activity and that enhancing TRP14 may present a new strategy for preventing bone resorption diseases.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25002534      PMCID: PMC4135626          DOI: 10.1128/MCB.00293-14

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  49 in total

Review 1.  Signal transduction by the JNK group of MAP kinases.

Authors:  R J Davis
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

Review 2.  Therapeutic approaches to bone diseases.

Authors:  G A Rodan; T J Martin
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

3.  Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL).

Authors:  M Matsumoto; T Sudo; T Saito; H Osada; M Tsujimoto
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

4.  A system for stable expression of short interfering RNAs in mammalian cells.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Science       Date:  2002-03-21       Impact factor: 47.728

5.  The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation.

Authors:  S E Lee; K M Woo; S Y Kim; H M Kim; K Kwack; Z H Lee; H H Kim
Journal:  Bone       Date:  2002-01       Impact factor: 4.398

6.  Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo.

Authors:  Tzu-Ching Meng; Toshiyuki Fukada; Nicholas K Tonks
Journal:  Mol Cell       Date:  2002-02       Impact factor: 17.970

Review 7.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

8.  Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor.

Authors:  S R Lee; K S Kwon; S R Kim; S G Rhee
Journal:  J Biol Chem       Date:  1998-06-19       Impact factor: 5.157

9.  NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1.

Authors:  Teruhito Yamashita; Zhenqiang Yao; Fang Li; Qian Zhang; I Raul Badell; Edward M Schwarz; Sunao Takeshita; Erwin F Wagner; Masaki Noda; Koichi Matsuo; Lianping Xing; Brendan F Boyce
Journal:  J Biol Chem       Date:  2007-05-07       Impact factor: 5.157

10.  Identifying the relative contributions of Rac1 and Rac2 to osteoclastogenesis.

Authors:  Yongqiang Wang; Dina Lebowitz; Chunxiang Sun; Herman Thang; Marc D Grynpas; Michael Glogauer
Journal:  J Bone Miner Res       Date:  2008-02       Impact factor: 6.741

View more
  4 in total

Review 1.  Thioredoxin-related protein of 14 kDa as a modulator of redox signalling pathways.

Authors:  Belén Espinosa; Elias S J Arnér
Journal:  Br J Pharmacol       Date:  2018-10-06       Impact factor: 8.739

2.  Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways.

Authors:  Long Xiao; Mengdan Zhong; Yu Huang; Jie Zhu; Wenkai Tang; Danyong Li; Jiandong Shi; Aiqing Lu; Huilin Yang; Dechun Geng; Hong Li; Zhirong Wang
Journal:  Aging (Albany NY)       Date:  2020-11-07       Impact factor: 5.682

3.  Unfractionated Heparin Promotes Osteoclast Formation in Vitro by Inhibiting Osteoprotegerin Activity.

Authors:  Binghan Li; Dan Lu; Yuqing Chen; Minghui Zhao; Li Zuo
Journal:  Int J Mol Sci       Date:  2016-04-22       Impact factor: 5.923

4.  Dehydrocostus lactone inhibits NFATc1 via regulation of IKK, JNK, and Nrf2, thereby attenuating osteoclastogenesis.

Authors:  Hye In Lee; Gong-Rak Lee; Jiae Lee; Narae Kim; Minjeong Kwon; Hyun Jin Kim; Nam Young Kim; Jin Ha Park; Woojin Jeong
Journal:  BMB Rep       Date:  2020-04       Impact factor: 4.778

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.